StressMarq biosciences - alpha synuclein oligomer antibody validation

该项目将使StressMarq公司（一家专门制造抗体的公司）和维多利亚大学的克里斯蒂博士的实验室能够研究一种新的α突触核蛋白聚合体。这种聚合物具有类似hasprion的性质，并且能够-当有活性时-催化宿主环境中发现的内源性α突触核蛋白单体在体内形成路易体。路易体是路易体痴呆的标志，通常被描述为帕金森病的一个子集（大约25%的帕金森病患者有这种病理）。该项目将涉及“映射”的病理表达和抗体的活性使用免疫组织化学对大鼠或小鼠脑切片收获的动物具有不同的控制神经系统的背景，一些常规的东西在克里斯蒂实验室。细胞培养的工作能力将显示抗体是否可以在这些细胞中诱导时中和路易体病理，如果成功，同样可以在大鼠中进行。

This project will allow StressMarq, a company that specializes in making antibodies, and Dr. Christie'slaboratory at the University of Victoria to investigate a novel alpha synuclein aggregate. This aggregate hasprion-like properties, and is able - when active - to catalyze the formation of Lewy Bodies in vivo fromendogenous alpha synuclein monomers found in the host environment. Lewy Bodies are a hallmark of LewyBody dementia, often described as being a subset of Parkinson's disease (approximately 25% of Parkinson'spatients have this pathology). The project will involve "mapping" the expression of the pathology and activityof the antibody using immunohistochemistry on rat or mouse brain slices harvested from animals with varyingcontrolled neurological backgrounds, something routinely done in the Christie laboratory. The ability to workwith cell culture would show if the antibody can neutralize the Lewy Body pathology when induced in thesecells, and if successful, the same could be carried out in rats.